Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 summary

Strategic focus and clinical pipeline

• Emphasis on estrogen receptor positive, HER2 negative breast cancer, representing 70% of cases.

• Lead asset palazestrant is a complete estrogen receptor antagonist in two pivotal phase III trials: OPERA-01 (2nd/3rd-line, monotherapy) and OPERA-02 (1st-line, in combination with ribociclib).

• OPERA-01 readout expected in the second half of 2026; OPERA-02 readout anticipated for late 2028.

• Additional asset OP3136, a KAT6 inhibitor, is in phase I trials for breast, prostate, and lung cancers, with first data expected late in the first half of 2026.

Competitive landscape and differentiation

• Recent positive interim results from Roche's LIDARA trial in the adjuvant setting highlight the efficacy of next-generation SERDs in wild type ESR1, endocrine-sensitive populations.

• Palazestrant distinguishes itself by enabling full dosing with multiple combination partners and maintaining high receptor occupancy.

• Phase II data show palazestrant plus ribociclib achieves longer progression-free survival in both ESR1 mutant and wild type populations compared to competitors.

• Market opportunity in 1st-line breast cancer is projected at $10–15 billion globally, with 2nd/3rd-line U.S. market at $5 billion.

Clinical trial design and regulatory considerations

• OPERA-01 and OPERA-02 trials are powered to independently assess efficacy in both ESR1 mutant and wild type populations.

• Success in OPERA-01 is defined as at least a two-month increase in progression-free survival, with unique potential to show monotherapy benefit in wild type patients.

• Combination partner selection for OPERA-02 shifted to ribociclib due to its superior survival benefit and evolving standard of care.

• Ongoing collaborations with Novartis (ribociclib) and Pfizer (atirmociclib) aim to extend palazestrant’s lifecycle and adapt to future standards.